Followers | 69 |
Posts | 10359 |
Boards Moderated | 0 |
Alias Born | 01/04/2007 |

Tuesday, January 05, 2021 9:55:55 AM
Recent MNMD News
- MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 • Business Wire • 02/20/2025 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/05/2025 10:28:45 PM
- MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference • Business Wire • 02/04/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2025 12:45:08 PM
- MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder • Business Wire • 01/30/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2024 09:31:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2024 09:31:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2024 09:30:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2024 09:39:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2024 09:30:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2024 09:28:56 PM
- MindMed to Be Added to the Nasdaq Biotechnology Index • Business Wire • 12/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2024 12:30:10 PM
- MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 12/16/2024 12:00:00 PM
- MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress • Business Wire • 12/11/2024 12:00:00 PM
- MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) • Business Wire • 12/05/2024 12:00:00 PM
- MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy • Business Wire • 12/03/2024 12:00:00 PM
- MindMed Announces New Employee Inducement Grants • Business Wire • 12/02/2024 12:00:00 PM
- MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer • Business Wire • 11/18/2024 12:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 09:05:16 PM
- MindMed to Participate in Upcoming Investor Conferences • Business Wire • 11/13/2024 12:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:25:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:15:10 PM
VAYK Proposes 100 million Buyback through Private Repurchases • VAYK • Feb 28, 2025 9:00 AM
ConnectM Eliminates an Additional $1.9 Million of Debt • CNTM • Feb 27, 2025 4:01 PM
Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc. • CAFI • Feb 27, 2025 9:00 AM
VPR Brands Secures Settlement Agreement With POP Vapor, Reinforcing Commitment to Intellectual Property Protection • VPRB • Feb 27, 2025 8:49 AM
Wytec Begins Sales of Its Multi-Government AI Threat Detection Sensor Technology • WYTC • Feb 27, 2025 7:05 AM
VAYK Issues Clerical Correction to Feb 18 News Regarding Shareholder Premium • VAYK • Feb 26, 2025 10:32 AM